JMP Securities Upgrades Pieris Pharmaceuticals (PIRS) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts PIRS Hot Sheet
Price: $13.60 --0%
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
JMP Securities earlier upgraded Pieris Pharmaceuticals (NASDAQ: PIRS) from Market Perform to Market Outperform with a price target of $10.00.
For an analyst ratings summary and ratings history on Pieris Pharmaceuticals click here. For more ratings news on Pieris Pharmaceuticals click here.
Shares of Pieris Pharmaceuticals closed at $3.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Compass Point Upgrades Circle Internet Group (CRCL) to Buy, 'a tactical trade into YE2026 and 4Q26 results'
- Canaccord Upgrades Joby Aviation Inc (JOBY) to Buy
- Macquarie Upgrades RHB Bank (RHBBANK:MK) to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
